Rosetta Genomics Ltd. announced consolidated earnings results for the fourth quarter and full year ended December 31, 2016. For the year, the company reported total revenues were USD 9,234,000 against USD 8,268,000 a year ago. Operating loss was USD 15,664,000 against USD 15,721,000 a year ago. Loss before income taxes was USD 16,267,000 against USD 17,326,000 a year ago. Net loss was USD 16,233,000 against USD 17,345,000 a year ago. Basic and diluted net loss per ordinary share was USD 9.31 against USD 13.79 a year ago. Net loss from continuing operations was USD 16,233,000 against USD 17,345,000 a year ago. Non-GAAP net loss from continuing operations was USD 14,816,000 against USD 14,872,000 a year ago. Basic and diluted net loss per ordinary share from continuing operations was USD 9.31 against USD 13.79 a year ago. Non-GAAP basic and diluted net loss per ordinary share was USD 8.50 against USD 11.82 a year ago.

For the quarter, the company reported net loss was USD 4,837,000 against USD 6,723,000 a year ago. Non-GAAP net loss was USD 4,117,000 against USD 2,653,000 a year ago. Basic and diluted net loss per ordinary share from continuing operations was USD 2.73 against USD 4.39 a year ago. Non-GAAP basic and diluted net loss per ordinary share was USD 2.32 against USD 1.73 a year ago. The operating loss for the fourth quarter of 2016 was USD 4.3 million, which included USD 162,000 of non-cash stock-based compensation expense, compared with an operating loss of USD 5.1 million for the fourth quarter of 2015, which included USD 261,000 of non-cash stock-based compensation expense as well as a USD 2.2 million adjustment to the gain on bargain purchase related to the acquisition of PersonalizeDx.

The company affirmed 2017 revenue and unit guidance for RosettaGX Reveal. For 2017, the company expects reveal revenue to be between USD 4.0 million and USD 5.0 million, and expects to process between 2,500 and 3,500 Reveal units during the year.